User:Ericantonhughes

SCH 900518 (narlaprevir), a novel inhibitor of the HCV NS3 protease, demonstrates potent antiviral activity with an EC90 of 40 nM in the HCV replicon assay. Narlaprevir is first HCV NS3 protease inhbitor to be co-administered with ritonavir to enhance the pharmacokinetics of narlaprevir. Narlapreivir has demonstrated potent antiviral activity in patient infected with HCV genotype 1 and is currently in Phase 2 clinical development.

Reesink HW, Bergmann JF, de Bruijne J, Weegink CJ, van Lier J, van Vliet A, Keung A, Li J, O’Mara E, Treitel MA, Hughes EA, Janssen HLA, de Knegt RJ Safety and Antiviral Activity of the HCV Protease Inhibitor SCH 900518 Administered as Monotherapy or in Combination with Peginterferon Alfa-2b to Naïve and Treatment-Experienced Chronic Hepatitis C Infected Patients  Abstract presented at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL) Copenhagen, Denmark, April 22-26, 2009.